Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Hanmi Pharmaceutical Company Limited: Clinical Trials & FDA Approval Profile

Hanmi Pharmaceutical Company Limited (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (5 recruiting now), 20 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.5%
Median Closed Enrollment vs National (145 pts)215 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Hanmi Pharmaceutical Company Limited
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)8 (5)
Completed vs Stopped Early20 / 1 (3.5%)
Median Closed Actual Enrollment215 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Hanmi Pharmaceutical Company Limited
Hospital Research SiteLocationShared Protocols
Asan Medical CenterSeoul8
Severance HospitalSeoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu6
Samsung Medical CenterSeoul, Gangnam-Gu4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Hanmi Pharmaceutical Company Limited
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07449754Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaPhase IIRECRUITING
NCT04044170Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationPhase IITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Hanmi Pharmaceutical Company Limited Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI